Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

Png, May Ee; Harris, Victoria; Grabey, Jenna; Hart, Nigel David; Jani, Bhautesh Dinesh; Butler, Daniel; Carson-Stevens, Andrew; Coates, Maria; Cureton, Lucy; Dobson, Melissa; Dorward, Jienchi; Evans, Philip; Francis, Nick; Gbinigie, Oghenekome Abisoye; Hayward, Gail; Holmes, Jane; Hood, Kerenza; Khoo, Saye; Ahmed, Haroon; Lown, Mark; Mckenna, Micheal; Mort, Sam; Nguyen-Van-Tam, Jonathan; Rahman, Najib; Richards, Duncan B; Thomas, Nicholas; Van Hecke, Oliver; Hobbs, FD Richard; Little, Paul; Yu, Ly-Mee; Butler, Christopher C; Petrou, Stavros

doi:10.3399/bjgp.2023.0444

All Outputs (4)

The effectiveness of pneumococcal vaccination in adults with common immune mediated inflammatory diseases: a UK wide study using data from the Clinical Practice Research Datalink Gold (2024)
Journal Article

Background The effectiveness of pneumococcal vaccination in people with common immune mediated inflammatory diseases (IMIDs) has not been evaluated. We investigated the effectiveness of pneumococcal vaccination in preventing respiratory morbidity a... Read More about The effectiveness of pneumococcal vaccination in adults with common immune mediated inflammatory diseases: a UK wide study using data from the Clinical Practice Research Datalink Gold.

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study (2024)
Journal Article

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association b... Read More about Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study.

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients (2024)
Journal Article

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 symptoms randomised to receive molnupiravir (n=253) or Usual Care (n... Read More about Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients.

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial (2024)
Journal Article

The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations. To evaluate the cost-effectiveness of molnupiravir relative to usual care alone among mainly vaccinated c... Read More about Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.